Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma

NCT07738159 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
QL1706
Lenvatinib
Chemotherapy

Interventions

DRUG: Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC
DRUG: EP/EC

Sponsor

West China Hospital